Stock Pulse
Johnson & Johnson (JNJ) faces ongoing talc-related lawsuits after a recent bankruptcy maneuver was rejected [1], [4]. Despite this, the company's core pharmaceutical and medtech businesses remain strong, with positive Phase III trial results for icotrokinra, a promising psoriasis treatment [2], [6]. JNJ is expected to announce Q1 2025 earnings on April 15th, with projections of slightly lower sales and earnings than previous estimates [4], [9]. Growth is anticipated in Innovative Medicines, but headwinds exist in MedTech and from biosimilar competition [4]. While JNJ stock has outperformed the market this year, concerns over lawsuits and potential pharmaceutical tariffs have contributed to recent stock price declines [4], [5], [10]. The company’s long-term outlook remains positive due to its strong financial position, consistent dividend increases, and innovative pipeline, though legal challenges persist [1].